|Bid||50.15 x 1000|
|Ask||0.00 x 800|
|Day's Range||50.75 - 53.65|
|52 Week Range||50.50 - 136.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Los Angeles-based company said it had a loss of 65 cents per share. Earnings, adjusted for stock option expense, were 2 cents per share. The results surpassed Wall Street expectations. The average ...
On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Puma Biotechnology (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
I am going to run you through how I calculated the intrinsic value of Puma Biotechnology Inc (NASDAQ:PBYI) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
Examining Puma Biotechnology Inc’s (NASDAQ:PBYI) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
The Los Angeles-based company said it had a loss of $1.71 per share. Losses, adjusted for stock option expense, were $1.03 per share. The results topped Wall Street expectations. The average estimate of ...
KemPharm, Inc. (NASDAQ:KMPH) ran into the end of last week on news related to the company’s lead development program. At the close of trade on Friday, KemPharm shares were going for around six dollars apiece, up more than 13% on the day’s open. Premarket on Monday, shares rose again to $6.35 but have since settled […] The post Here’s What’s Moving KemPharm And Puma Biotechnology appeared first on Market Exclusive.
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Puma's licensing agreement for breast cancer drug Nerlynx won't inhibit takeover interest for Puma, an analyst said Tuesday.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Short interest is moderate for PBYI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold PBYI had net inflows of $286 million over the last one-month.
In case you missed it, here are some of Benzinga's top stories from Wednesday, Jan. 24, 2018. A Pharma Trade From Goldman Jayson Derrick outlines a bull and bear call on Catelent, Inc (NYSE: CTLT ) and ...
Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.
Puma Biotechnology’s shares are getting pounded today after its breast cancer drug neratinib suffered a regulatory setback that makes a 2018 European launch unlikely. One analyst says the news “makes the M&A narrative more challenging.”
Puma Biotechnology Inc (NASDAQ:PBYI) is down 27% in early trading Wednesday after announcing a disappointing outcome from a meeting with European regulators over its breast cancer drug neratinib. The biotech met with regulators at the European Medicines Agency (EMA) to go over outstanding issues with the marketing application for neratinib, but failed to convince them that the drug is approvable. CHMP indicated that, in its opinion, the benefit risk assessment is negative as the study results are based on evidence from a single pivotal trial and the 2- and 5-year invasive disease free survival (iDFS) benefits observed to-date may lack sufficient clinical relevance.
Puma Biotechnology Inc (NASDAQ: PBYI ) could face a setback in the launch of its breast cancer drug neratinib, as the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, ...